Phase II trial of durvalumab plus tremelimumab with concurrent radiotherapy (RT) in patients (pts) with localized muscle invasive bladder cancer (MIBC) treated with a selective bladder preservation approach: IMMUNOPRESERVE-SOGUG trial

Xavier Garcia-del-Muro,Begoña P. Valderrama,Ana Medina,M. Andres Cuellar,Olatz Etxaniz,Regina Gironés Sarrió,María José Juan-Fita,Ferran Ferrer,Isabel Miras Rodríguez,Guillermo Lendínez-Cano,Roberto de Haro Piedra,Arturo Candal Gómez,Venancio Chantada Abal,Oscar Buisan,Salvador Villà,José Luis Pontones,Erica Collado,Jose L Dominguez-Escrig,Yashmina Murria,F. Vigués

Phase II trial of durvalumab plus tremelimumab with concurrent radiotherapy (RT) in patients (pts) with localized muscle invasive bladder cancer (MIBC) treated with a selective bladder preservation approach: IMMUNOPRESERVE-SOGUG trial

2021

4505Background: Bladder-preserving combined-modality therapies constitute an alternative to radical cystectomy for selected pts with MIBC. In preclinical studies, combination of radiation and dual ...

Keywords:

Cystectomy
muscle invasive
Medicine
in patient
Tremelimumab
bladder preservation
Durvalumab
Urology
Radiation therapy
Bladder cancer

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations